Vol 71, No 5 (2013)
Original articles
Published online: 2013-05-19

open access

Page views 1183
Article views/downloads 1259
Get Citation

Connect on Social Media

Connect on Social Media

Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty

Wiktor Kuliczkowski, Joanna Urbaniak, Jonas Hallén, Mieczysław Woźniak, Lech Poloński, Andrzej Mysiak, Dan Atar, Marian Zembala, Victor Serebruany
Kardiol Pol 2013;71(5):453-463.

Abstract

Background: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) play a role in heart remodelling after acutemyocardial infarction (MI). Their activity is connected with outcome and heart failure development. There is little data on MMPand TIMP activity changes in the setting of ST elevation MI (STEMI) treated with primary percutaneous coronary intervention (pPCI).

Aim: To assess the dynamics of activity of MMP-2 and MMP-9 and their endogenous inhibitors TIMP-1 and TIMP-2 in thecourse of invasive treatment of STEMI.

Methods: The study included 95 patients (age 61.8 ± 12.4 years; 35 women) treated with pPCI with stent implantation dueto 100% closure of the target vessel in a setting of STEMI. We measured the activity of MMP-2 and MMP-9 (by zymography,expressed with arbitrary units, AU), CK-MB (U/L), troponin I (ng/mL), TIMP-1, TIMP-2 (ng/mL) concentrations in a peripheralblood before the pPCI, immediately after and 3, 6, 12, 24 and 48 h after the procedure. Left ventricular ejection fraction(LVEF) was estimated at the hospital discharge using the Simpson method. There were two control groups: 15 healthy personsand 15 patients with stable coronary artery disease matched for age and sex with the studied group.

Results: The abrupt opening of the target vessel did not produce an early increase in the activity of the MMPs. Their activitywas high at the beginning and slowly lowered with time after pPCI so that at 12, 24 and 48 h after pPCI their activity wassignificantly lower than before and immediately after the pPCI (p < 0.05 for all comparisons). The abrupt opening of thetarget vessel did not produce significant changes in the TIMP concentration. Only the TIMP-1 showed a slow increase inconcentration and achieved a significantly higher level 48 h after the procedure compared to its concentration before andimmediately after pPCI (p < 0.05). In 14 patients (15% of the studied group), the post procedure TIMI flow was estimatedas lower than 3 (TIMI 1 or 2). There was significantly higher MMP-9 activity in this group before, immediately after and up to3 h after PCI compared to the group with good angiographic effect (TIMI = 3 after procedure). Patients with lowered LVEF(< 50%) at hospital discharge had higher MMP-9 activity immediately after and 3 h after pPCI compared to patients withpreserved LVEF. The same relation was observed for TIMP-2 level, where patients with a higher level before and immediatelyafter pPCI had lowered LVEF at discharge.

Conclusions: 1. The activity level of MMP-2 and MMP-9 is elevated during the STEMI acute phase and falls 12 h after successfulpPCI, while TIMP-1 concentration only rises 48 h after the procedure. 2. The abrupt opening of the target vessel inSTEMI does not produce acute changes in MMP-2, MMP-9 activity or TIMP-1 and TIMP-2 concentration. 3. The ‘no-reflow’phenomenon in STEMI patients occurs more often in those with higher MMP-9 activity before pPCI. 4. Lowered LVEF athospital discharge is observed in patients with higher periprocedural MMP-9 activity and TIMP-2 level.

Article available in PDF format

View PDF Download PDF file



Polish Heart Journal (Kardiologia Polska)